Esophageal Squamous Carcinoma (ESCC) Market Expected to Witness Significant Growth Through 2036, Driven by Advancements in Immunotherapy, Targeted Therapies, and Expanding Treatment Landscape | DelveInsight

The Esophageal Squamous Carcinoma (ESCC) market is expected to witness significant growth across the Seven Major Markets (7MM) during the forecast period (2022-2036). Market expansion is anticipated to be driven by the increasing incidence of esophageal cancer, growing adoption of immune checkpoint inhibitors, advancements in multimodal treatment strategies, improving biomarker-guided therapy, and the anticipated launch of promising pipeline candidates. Novel antibody-drug conjugates (ADCs), bispecific antibodies, and targeted therapies are expected to reshape the ESCC treatment landscape over the coming years.

DelveInsight's "Esophageal Squamous Carcinoma (ESCC) Market Insights, Epidemiology, and Market Forecast-2036" report provides a comprehensive assessment of disease epidemiology, current treatment practices, marketed and emerging therapies, market trends, pricing analysis, therapy uptake, reimbursement landscape, and market forecasts across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report further evaluates patient burden, competitive intelligence, key opinion leader perspectives, and commercial opportunities expected to shape the ESCC market through 2036.

The report also delivers detailed insights into historical and forecasted market performance, epidemiological trends, treatment algorithms, unmet needs, SWOT analysis, pricing dynamics, and the evolving competitive landscape to support strategic decision-making for stakeholders operating in the oncology sector.

To know more about the Esophageal Squamous Carcinoma (ESCC) market, epidemiology, and forecast, Click here:
https://www.delveinsight.com/sample-request/esophageal-squamous-carcinoma-market?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Key Takeaways from the Esophageal Squamous Carcinoma (ESCC) Market Report

• The Esophageal Squamous Carcinoma (ESCC) market is expected to expand significantly across the 7MM during the forecast period (2022-2036), supported by increasing adoption of immunotherapy, expanding use of targeted therapies, and anticipated launches of emerging late-stage pipeline candidates.
• Esophageal cancer is the seventh most common cancer worldwide and the sixth leading cause of cancer-related mortality, with squamous cell carcinoma remaining the predominant histological subtype globally.
• According to the American Cancer Society (2026), approximately 22,530 new cases of esophageal cancer are expected to be diagnosed in the United States, including 17,580 cases in men and 4,950 cases in women.
• Tobacco smoking and alcohol consumption account for nearly 75-90% of ESCC cases, exerting a synergistic effect that substantially increases disease risk.
• Currently marketed therapies include TEVIMBRA (tislelizumab), KEYTRUDA (pembrolizumab), and OPDIVO (nivolumab), while emerging therapies such as Ifinatamab Deruxtecan, ALE.P02, Volrustomig, Futibatinib, and TER-2013 are expected to further strengthen the future treatment landscape.
• In May 2025, the first patient was dosed in the Phase III IDeate-Esophageal01 trial evaluating Ifinatamab Deruxtecan versus investigator's choice of chemotherapy in patients with unresectable advanced or metastatic ESCC who progressed after platinum-containing chemotherapy and immune checkpoint inhibitor treatment.

Key Factors Driving the Esophageal Squamous Carcinoma (ESCC) Market

Growing Burden of Esophageal Cancer
The increasing incidence of esophageal cancer, together with aging populations and continued exposure to major risk factors such as tobacco and alcohol, continues to expand the treatable patient population and drive demand for innovative therapies.

Rapid Expansion of Immunotherapy
The integration of PD-1/PD-L1 immune checkpoint inhibitors, including TEVIMBRA, KEYTRUDA, and OPDIVO, into first-line and subsequent treatment settings is significantly improving treatment outcomes and driving market growth.

Advancing Late-stage Pipeline
Promising investigational therapies including Ifinatamab Deruxtecan, ALE.P02, Volrustomig, Futibatinib, and TER-2013 are progressing through clinical development and are expected to expand future treatment options for patients with advanced ESCC.

Increasing Adoption of Multimodal Treatment Strategies
The growing use of multimodal approaches incorporating surgery, chemoradiotherapy, chemotherapy, targeted therapy, and immunotherapy is improving clinical outcomes and supporting continued market expansion across the 7MM.

Esophageal Squamous Carcinoma (ESCC) Market Analysis

Esophageal Squamous Carcinoma remains one of the most aggressive malignancies worldwide, with high recurrence rates and poor long-term survival despite advances in treatment. Current management involves multimodal treatment strategies including surgery, neoadjuvant chemoradiotherapy, definitive chemoradiotherapy, platinum- and fluoropyrimidine-based chemotherapy, targeted therapy, and immune checkpoint inhibitors. The recent expansion of immunotherapy-based regimens has significantly improved treatment outcomes for patients with advanced disease. According to DelveInsight, continued innovation in antibody-drug conjugates, bispecific antibodies, targeted therapies, and immunotherapy combinations, together with increasing healthcare expenditure across the 7MM, is expected to support sustained growth of the Esophageal Squamous Carcinoma market through 2036.

Get a Free sample for the Esophageal Squamous Carcinoma (ESCC) Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/sample-request/esophageal-squamous-carcinoma-market?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Esophageal Squamous Carcinoma (ESCC) Competitive Landscape

The Esophageal Squamous Carcinoma (ESCC) treatment landscape has evolved significantly with the integration of immune checkpoint inhibitors, targeted therapies, and multimodal treatment approaches. Current management includes surgery, neoadjuvant chemoradiotherapy, definitive chemoradiotherapy, platinum- and fluoropyrimidine-based chemotherapy, and immunotherapy depending on disease stage and patient fitness. Approved immunotherapies such as TEVIMBRA (tislelizumab), KEYTRUDA (pembrolizumab), and OPDIVO (nivolumab) have transformed the treatment paradigm for advanced ESCC, while several novel antibody-drug conjugates (ADCs), bispecific antibodies, and targeted therapies are progressing through clinical development and are expected to further expand treatment options.

Leading companies advancing the ESCC pipeline include Merck/Daiichi Sankyo, Alentis Therapeutics, Taiho Oncology, AstraZeneca, Terremoto Biosciences, and others developing innovative therapies for advanced or metastatic disease.

Ifinatamab Deruxtecan: Merck/Daiichi Sankyo
Ifinatamab Deruxtecan (I-DXd) is an investigational first-in-class B7-H3-directed antibody-drug conjugate (ADC) developed using Daiichi Sankyo's proprietary DXd ADC technology. The therapy consists of a humanized anti-B7-H3 IgG1 monoclonal antibody linked to a topoisomerase I inhibitor payload (DXd) through a cleavable tetrapeptide linker. It is currently being evaluated in the Phase III IDeate-Esophageal01 trial for patients with unresectable advanced or metastatic ESCC following platinum-containing chemotherapy and immune checkpoint inhibitor treatment. In May 2025, the first patient was dosed in the pivotal Phase III trial, marking a major milestone in the development of this promising therapy.

ALE.P02: Alentis Therapeutics
ALE.P02 is a first-in-class CLDN1-targeted antibody-drug conjugate (ADC) designed by linking a potent tubulin inhibitor to an antibody targeting a unique CLDN1 epitope expressed on squamous cancer cells. The therapy aims to deliver targeted cytotoxic activity while minimizing systemic toxicity compared with conventional chemotherapy. ALE.P02 is currently being evaluated in a Phase I/II clinical trial involving patients with selected CLDN1-positive solid tumors, including ESCC. In November 2024, the US FDA granted Fast Track Designation (FTD) to ALE.P02 for patients with CLDN1-positive squamous solid tumors.

Futibatinib (TAS-120): Taiho Oncology
Futibatinib is a next-generation irreversible FGFR1-4 inhibitor designed to overcome resistance associated with ATP-competitive FGFR inhibitors. The therapy has demonstrated encouraging antitumor activity in FGFR-altered tumors and is currently being evaluated in Phase II clinical development for ESCC and other advanced solid tumors.

Volrustomig (MEDI5752): AstraZeneca
Volrustomig (MEDI5752) is a PD-1/CTLA-4 bispecific humanized IgG1 monoclonal antibody engineered to selectively inhibit PD-1 while enhancing CTLA-4 blockade on activated T cells. The therapy is currently being investigated in Phase II clinical trials involving patients with advanced or metastatic solid tumors, including ESCC, and has the potential to further strengthen immunotherapy-based treatment strategies.

TER-2013: Terremoto Biosciences
TER-2013 is an investigational targeted therapy currently undergoing clinical development for patients with advanced Esophageal Squamous Carcinoma. The therapy represents one of several next-generation pipeline assets expected to broaden future treatment options for ESCC patients.

Discover more about therapies expected to transform the Esophageal Squamous Carcinoma (ESCC) market @ Esophageal Squamous Carcinoma Treatment Landscape

Recent Developments in the Esophageal Squamous Carcinoma (ESCC) Market

• In May 2025, the first patient was dosed in the Phase III IDeate-Esophageal01 trial evaluating Ifinatamab Deruxtecan versus investigator's choice of chemotherapy in patients with unresectable advanced or metastatic ESCC following platinum-containing chemotherapy and immune checkpoint inhibitor treatment.
• At the ESMO Congress 2025, a Phase III study demonstrated that adding LENVIMA to KEYTRUDA plus chemotherapy did not improve overall survival compared with the standard treatment regimen in ESCC.
• In March 2025, the US FDA approved TEVIMBRA (tislelizumab) in combination with platinum-based chemotherapy as a first-line treatment for adults with unresectable or metastatic ESCC expressing PD-L1 ≥1.
• In March 2025, Japan approved TEVIMBRA for the treatment of unresectable advanced or recurrent esophageal cancer, followed by reimbursement listing in May 2025 and commercial launch in July 2025.
• In November 2024, ALE.P02 received US FDA Fast Track Designation for patients with CLDN1-positive squamous solid tumors, including ESCC.

What is Esophageal Squamous Carcinoma (ESCC)?

Esophageal Squamous Carcinoma (ESCC) is the most common histological subtype of esophageal cancer worldwide, arising from the squamous epithelial cells lining the esophagus. The disease is strongly associated with tobacco smoking, alcohol consumption, poor nutrition, and certain environmental risk factors. ESCC is frequently diagnosed at an advanced stage because of nonspecific early symptoms, contributing to poor long-term survival despite advances in multimodal therapy. Current treatment includes surgery, chemoradiotherapy, chemotherapy, targeted therapy, immunotherapy, and supportive care depending on disease stage and patient characteristics.

Esophageal Squamous Carcinoma (ESCC) Epidemiology Segmentation

The DelveInsight report provides a comprehensive epidemiological assessment of Esophageal Squamous Carcinoma across the Seven Major Markets (7MM) during 2022-2036, segmented into:
• Total Incident Cases of Esophageal Cancer
• Age-specific Cases of Esophageal Cancer
• Histology-specific Cases of Esophageal Cancer (Squamous/Non-squamous)
• Gender-specific Cases of Esophageal Cancer
• Mutation-specific Cases of Esophageal Cancer
• Stage-specific Cases of Esophageal Cancer
• Line-wise Treated Cases of Esophageal Cancer across the United States, EU4 and the United Kingdom, and Japan.

Download the report to explore detailed epidemiology trends, emerging therapies, competitive intelligence, and commercial opportunities in the Esophageal Squamous Carcinoma (ESCC) market:
https://www.delveinsight.com/sample-request/esophageal-squamous-carcinoma-market?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Scope of the Esophageal Squamous Carcinoma (ESCC) Market Report

• Study Period: 2022-2036
• Coverage: Seven Major Markets (7MM) - United States, Germany, France, Italy, Spain, the United Kingdom, and Japan
• Key Companies: Merck/Daiichi Sankyo, Alentis Therapeutics, Taiho Oncology, AstraZeneca, Terremoto Biosciences, and others
• Current Therapies: TEVIMBRA (tislelizumab), KEYTRUDA (pembrolizumab), OPDIVO (nivolumab), platinum- and fluoropyrimidine-based chemotherapy, surgery, chemoradiotherapy
• Emerging Therapies: Ifinatamab Deruxtecan, ALE.P02, Futibatinib, Volrustomig, TER-2013, and others
• Epidemiology Segmentation: Total incident cases, age-specific cases, histology-specific cases, gender-specific cases, mutation-specific cases, stage-specific cases, and line-wise treated cases
• Market Insights: Historical and forecasted market size, therapy uptake, pricing trends, analogue assessment, competitive landscape, SWOT analysis, unmet needs, and market forecasts through 2036
• Market Access: Country-specific reimbursement and Health Technology Assessment (HTA) landscape across the 7MM
• Additional Coverage: Patient journey, Key Opinion Leader (KOL) perspectives, reimbursement dynamics, market access strategies, analyst views, and competitive benchmarking.

To learn more about the Esophageal Squamous Carcinoma (ESCC) market, epidemiology, and emerging treatment landscape, visit:
https://www.delveinsight.com/sample-request/esophageal-squamous-carcinoma-market?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents

• Esophageal Squamous Carcinoma (ESCC) Market Report Introduction
• Esophageal Squamous Carcinoma (ESCC) Market Executive Summary
• Key Events
• Esophageal Squamous Carcinoma (ESCC) Epidemiology and Market Forecast Methodology
• Esophageal Squamous Carcinoma (ESCC) Market Overview at a Glance
• Esophageal Squamous Carcinoma (ESCC) Clinical Landscape Analysis
• Disease Background and Overview
• Esophageal Squamous Carcinoma (ESCC) Epidemiology Analysis
• Esophageal Squamous Carcinoma (ESCC) Patient Population Analysis
• Patient Journey
• Marketed Therapies
• Emerging Therapies
• Competitive Landscape
• Esophageal Squamous Carcinoma (ESCC) Market Size Analysis (2022-2036)
• Market Size by Therapy
• Drug Uptake Analysis
• Market Access and Reimbursement
• Key Opinion Leader (KOL) Views
• Unmet Needs
• SWOT Analysis
• Analyst Views
• Appendix

Media Contact
Company Name: DelveInsight
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +1-469-945-7679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.